Shares of Spyre Therapeutics (SYRE) have gained 14.7% over the past four weeks to close the last trading session at $14.93, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$53.50 indicates a potential upside of 258.3%.The mean estimate comprises 10 short-term price targets with a standard deviation of $16.36. While the lowest estimate of$21 indicates a 40.7% increase from the c ...